CKPT Checkpoint Therapeutics 添加自选 3.300 -0.130-3.79% 收盘价 11/18 16:00 (美东) 3.380 +0.080+2.42% 盘后19:21 (美东) 1.61亿总市值-1803市盈率TTM 3.470最高价3.250最低价77.97万股成交量3.440今开3.430昨收260.22万成交额2.24%换手率亏损市盈率(静)4883.25万总股本3.97052周最高-12.79市净率1.15亿...
View Checkpoint Therapeutics (CKPT) stock price, news, historical charts, analyst ratings, financial information and quotes on Futubull. Trade commission-free with the Futubull stock trading app.
CKPT | Complete Checkpoint Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Checkpoint Therapeutics started at buy with $18 stock price target at B. Riley Jun. 9, 2021 at 8:21 a.m. ETby Tomi Kilgore ARMISTICE CAPITAL, LLC Acquires Significant Stake in Checkpoint Therapeutics Inc Nov. 15, 2024 at 6:42 a.m. ETon GuruFocus.com ...
坎托菲茨杰拉德公司:维持Checkpoint Therapeutics(CKPT.US)评级,由增持调整至增持评级, 目标价由19.00美元调整至14.00美元。 Checkpoint Therapeutics(CKPT.US)公司简介:Checkpoint Therapeutics Inc 是一家位于美国的免疫肿瘤生物制药公司,专注于为实体瘤癌症患者提供新型非化疗免疫增强联合疗法的收购、开发和商业化。 其获得...
Get the latest Checkpoint Therapeutics Inc. (CKPT) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.
Checkpoint Therapeutics, Inc. Common Stock (CKPT) Dividend History “股息历史记录”页面是一个单独页面,可查看所有汇总的股息支付信息。请访问我们的股息日历:我们的合作伙伴 Quotemedia 提供了下个月的除息日期。 Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. ...
智通财经获悉，日前，Checkpoint Therapeutics(CKPT.US)宣布已向美国FDA重新提交其PD-L1靶向抗体cosibelimab的生物制品许可申请(BLA)，用以治疗转移性或局部晚期皮肤鳞状细胞癌(cSCC)患者，这些患者不适合接受根治性手术或放射疗法。资料显示，Cosibelimab是一款潜在的差异化、高亲和力、全人源IgG1亚型单抗，可直接与PD...
智通财经APP获悉,日前,Checkpoint Therapeutics(CKPT.US)宣布已向美国FDA重新提交其PD-L1靶向抗体cosibelimab的生物制品许可申请(BLA),用以治疗转移性或局部晚期皮肤鳞状细胞癌(cSCC)患者,这些患者不适合接受根治性手术或放射疗法。 资料显示,Cosibelimab是一款潜在的差异化、高亲和力、全人源IgG1亚型单抗,可直接与PD...
Checkpoint Therapeutics Inc Stock forecast & analyst price target predictions based on 1 analysts offering 12-months price targets for CKPT in the last 3 months.